Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 68,679 Personalis, Inc. $PSNL

Connor Clark & Lunn Investment Management Ltd. acquired a new position in Personalis, Inc. (NASDAQ:PSNL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 68,679 shares of the company’s stock, valued at approximately $451,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.08% of Personalis as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in PSNL. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Personalis by 67.0% in the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 92,841 shares of the company’s stock worth $609,000 after purchasing an additional 37,258 shares during the period. Alpha Wealth Funds LLC bought a new position in shares of Personalis during the second quarter valued at about $66,000. Aberdeen Group plc grew its stake in shares of Personalis by 3.2% during the second quarter. Aberdeen Group plc now owns 1,759,497 shares of the company’s stock valued at $11,542,000 after buying an additional 54,713 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after buying an additional 101,706 shares during the period. Finally, Focus Partners Wealth bought a new stake in shares of Personalis in the 1st quarter valued at about $47,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

PSNL has been the topic of several recent research reports. Morgan Stanley raised their price target on Personalis from $5.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. HC Wainwright upped their price target on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. BTIG Research raised their price target on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Finally, Guggenheim boosted their price objective on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.29.

Personalis Trading Up 0.5%

Shares of Personalis stock opened at $8.28 on Friday. Personalis, Inc. has a 12-month low of $2.83 and a 12-month high of $10.95. The company has a market cap of $735.26 million, a P/E ratio of -9.41 and a beta of 1.92. The company’s fifty day simple moving average is $7.83 and its two-hundred day simple moving average is $6.31.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The firm had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts predict that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Insiders Place Their Bets

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of Personalis stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.80% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.